These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1043 related articles for article (PubMed ID: 20826764)

  • 1. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
    Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
    Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
    Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
    J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
    Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
    Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinguishing the progression of an endometrioma: Benign or malignant?
    Bastu E; Onder S; Demiral I; Ozsurmeli M; Keskin G; Takmaz O; Ozaltin S; Gorgen H; Gungor M; Yavuz E; Buyru F
    Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():79-84. PubMed ID: 30245441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
    Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
    Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF; Tsai EM; Chen CC; Wu CC; Er TK
    Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
    Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
    Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
    [No Abstract]   [Full Text] [Related]  

  • 12. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
    Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
    Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks.
    Murakami R; Matsumura N; Brown JB; Higasa K; Tsutsumi T; Kamada M; Abou-Taleb H; Hosoe Y; Kitamura S; Yamaguchi K; Abiko K; Hamanishi J; Baba T; Koshiyama M; Okuno Y; Yamada R; Matsuda F; Konishi I; Mandai M
    Am J Pathol; 2017 Oct; 187(10):2246-2258. PubMed ID: 28888422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
    Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
    Guan B; Wang TL; Shih IeM
    Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA.
    Hoshino H; Inoue D; Shinagawa A; Yoshida H; Shigeto S; Matsuda K; Akama TO; Yoshida Y; Kobayashi M
    Hum Cell; 2024 Jul; 37(4):1184-1193. PubMed ID: 38573494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.